ANGLE plc (DWV) Q2 2025 Earnings Report

ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.

During the ANGLE 2025 Interim Results Call, CEO Andrew Newland provided comprehensive guidance on the company's financial and operational progress for the first half of the fiscal year. Despite facing adverse market conditions that pressured revenue, with pharma revenue down and product revenue flat compared to the prior year, ANGLE has made significant strides in commercialization and development. Key achievements include the completion of three major pharma projects with Eisai and AstraZeneca, the development of the DNA dual analysis using Illumina's NGS assay, and the commencement of a collaboration with Myriad Genetics for large-scale commercialization of the Parsortix system. The company has maintained tight cost control, reducing operating expenditure by 12%, and holds a cash position of GBP 6.6 million, with a runway extending into Q1 2026. Despite the challenging environment, ANGLE anticipates further developments with multiple large pharma and med tech companies and is actively pursuing additional funding sources to ensure continued growth and innovation in its cancer diagnostic solutions.